Dow Tumbles Over 1%; Nio Shares Edge Lower After Q2 Results

Company Performance - Nio reported fiscal second-quarter revenue of 19.01 billion Chinese yuan ($2.65 billion), representing a year-over-year increase of 9.0% and a sequential growth of 57.9% [2] - The company reported an adjusted loss per share of 1.85 yuan (25 cents), an improvement from a loss of 2.21 yuan in the same quarter last year, and better than analysts' expectations of a 30 cents loss [3] - For Q3 2025, Nio expects vehicle deliveries to be between 87,000 and 91,000 units, indicating a growth of approximately 40.7% to 47.1% compared to the same period in 2024 [3] Stock Movements - Cytokinetics, Incorporated shares surged 38% to $48.74 following positive clinical trial results for Aficamten [8] - Carisma Therapeutics, Inc. saw a 90% increase in shares to $0.4088 after announcing a $5 million investment from Ocugen [8] - United Therapeutics Corporation shares rose 39% to $422.36 after its TETON-2 study met primary efficacy endpoints [8] - CleanCore Solutions, Inc. shares dropped 58% to $2.8800 due to a PIPE agreement announcement [8] - Canopy Growth Corporation shares fell 16% to $1.5095 following a $200 million offering disclosure [8] - Celularity Inc. shares decreased by 37% to $2.4500 after receiving a Nasdaq notification regarding Form 10-Q [8] Market Overview - U.S. stocks traded lower, with the Dow Jones index down 1.08% to 45,052.65, NASDAQ down 1.60% to 21,111.52, and S&P 500 down 1.32% to 6,374.93 [1] - European shares also declined, with the eurozone's STOXX 600 falling 1.17% and major indices in Spain, London, Germany, and France also experiencing losses [7] - Asian markets closed mostly lower, with Japan's Nikkei 225 gaining slightly while other major indices in Hong Kong, China, and India fell [9]